Results 71 to 80 of about 240,836 (199)

Prothrombin complex concentrate for oral factor Xa inhibitor reversal prior to urgent invasive procedures

Transfusion, Volume 66, Issue 6, Page 1203-1209, June 2026.
Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea, Alex Osnis, Awan Kashoua, Orli Avnery, Gilad Itchaki, Shuli Isman, Tali Tohami, Osnat Jarchowsky‐Dolberg, Martin Ellis   +8 more
wiley   +1 more source

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Oral anticoagulation (OAC) reduces stroke risk by at least two thirds and mortality by one fourth. The threshold for net clinical benefit of OAC is met when stroke risk exceeds 1%–2% per year. Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists (VKAs) in most patients, including in the elderly and chronic kidney disease ...
Nicolas Johner, Baris Gencer
wiley   +1 more source

Safety and Efficacy of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Cerebrovascular Ischemic Outcomes in Non‐Valvular Atrial Fibrillation: A Systematic Review and Meta‐Analysis

Clinical Cardiology, Volume 49, Issue 4, April 2026.
Direct Oral Anticoagulants (DOACs) were associated With lower rates of cerebrovascular ischemic events and major bleeding compared With Vitamin K antagonists in non‐valvular atrial fibrillation, With similar mortality. These findings support DOACs as the preferred anticoagulant strategy for stroke prevention in contemporary clinical practice.
Anam Nasir, Naqash Anwar, Abdullah Bin Kamran, Ayesha Muhammad, Ali Haider, Muhammad Mubashar, Fatima Tariq, Mostafa Helou, Besher Shami   +8 more
wiley   +1 more source

Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report

, 2022
The management of patients on direct oral anticoagulants (DOACs) who require emergent cardiac surgery is slowly evolving. The introduction of andexanet alfa, a novel antidote for apixaban and rivaroxaban, added a specific reversal agent to our ...
Williams, Campbell, Mangunta, Venkat R, MD, Tanaka, Kenichi, McNeil, John S., Mangunta, Venkat, Guerra, Jessica, Kern, John, Brenner, Brian, McNeil, John S, Littlewood, Keith, Kenichi Tanaka, John Kern, Brian Brenner, Jessica Guerra, Keith Littlewood, John S. McNeil, Campbell Williams, Venkat Mangunta   +17 more
core   +1 more source

Andexanet alpha-induced heparin resistance treated by nafamostat mesylate in a patient undergoing total aortic arch repair for Stanford type A acute aortic dissection: a case report

JA Clinical Reports
Background Andexanet alfa, an anti-Xa inhibitor antagonist, induces heparin resistance. Here, we report a case of successful management of cardiopulmonary bypass with andexanet alfa-induced heparin resistance using nafamostat mesylate.
Yasuhito Suzuki, Mutsuhito Kikura, Shingo Kawashima, Tetsuro Kimura, Yoshiki Nakajima   +4 more
doaj   +1 more source

Excessive Apixaban Concentrations in a Bleeding Patient Treated With Pharmacological Reversal and Extracorporal Removal—A Case Report

Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.
Excessive apixaban concentrations in a bleeding patient leading to impaired coagulation and treatment with pharmacological reversal and extracorporal removal. ABSTRACT In trauma, even therapeutic apixaban levels can significantly exacerbate bleeding.
Richard Felix Kraus, Johanna Rosenberger, Alexander Dejaco, Michael Paal, Christina Hart, Ralph Burkhardt, Martin Georg Kees   +6 more
wiley   +1 more source

Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values

Clinical and Applied Thrombosis/Hemostasis, 2019
Recombinant coagulation factor Xa (FXa), inactivated Zh-zo, also known as andexanet alfa (AA), is a modified version of human FXa that has been developed to neutralize FXa inhibitors.
Fakiha Siddiqui BDS, Alfonso Tafur MD, Lorenzo Storino Ramacciotti BS, Walter Jeske PhD, Debra Hoppensteadt PhD, Eduardo Ramacciotti MD, PhD, Omer Iqbal MD, FACC, FESC, Jawed Fareed PhD   +7 more
doaj   +1 more source

82EMF Andexanet Alfa Increases Thrombotic Events Versus 4F-PCC for fXa Inhibitor-Related Intracranial Hemorrhage in Veterans

Annals of Emergency Medicine
Two hemostatic agents are commonly used to reverse factor Xa (fXa) inhibitor-related intracerebral hemorrhage (ICH): andexanet alfa (AA) or 4-factor prothrombin complex concentrate (4F-PCC).
M. Rech, E. Budde, C. Evans, D. Finch, Ying-Lin Xia, Z. Huo, Jin H. Han   +6 more
semanticscholar   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 250-258, April 2026.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

Reversing factor Xa inhibitors - clinical utility of andexanet alfa [PDF]

, 2017
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal ...
Lavender, Robert, Bhansali, Hardik, Paje, David G, Mahan, Charles E, Kaatz, Scott, Gibbs, Joseph J   +5 more
core